Lisa LaVange, director of the Office of Biostatistics in the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), has been elected the 113th president of the ASA. LaVange will serve a one-year term as presidentelect beginning January 1,2017. Her term as president becomes effective January 1, 2018. The ASA membership also elected G. David Williamson, senior science adviser at the U.S. Centers for Disease Control and Prevention (CDC), as an ASA vice president.
展开▼
机译：美国食品药品监督管理局（FDA）药品评估与研究中心（CDER）生物统计学办公室主任Lisa LaVange当选为ASA的第113任主席。 LaVange自2017年1月1日起将担任为期一年的总统大选。她的总统任期将于2018年1月1日生效。ASA成员还选举了美国疾病控制与预防中心（CDC）的高级科学顾问G. David Williamson担任ASA副总裁。
展开▼
